Clinical Trials Directory

Trials / Completed

CompletedNCT06770946

The Effect of Amniotic Membrane Application on Post-Cesarean Wound Healing and Cosmetic Outcomes

The Effect of Amniotic Membrane Application on Post-Cesarean Wound Healing and Cosmetic Outcomes: a Double-Blind, Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
372 (actual)
Sponsor
Yuzuncu Yil University · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

This clinical trial evaluates the effectiveness of amniotic membrane application during cesarean delivery in reducing post-surgical complications and improving wound healing and cosmetic outcomes in women aged 18-40 undergoing their first cesarean section. The primary questions this study aims to answer are: 1. Compared to standard care, Does the amniotic membrane reduce surgical site infections and wound dehiscence? 2. Does the amniotic membrane improve patient satisfaction with cosmetic outcomes? Participants were randomized into two groups: the intervention group received an amniotic membrane application over the cesarean incision site, while the control group underwent cesarean delivery without membrane application. Outcomes were assessed at predefined postoperative intervals, focusing on wound healing, pain levels, and cosmetic satisfaction.

Detailed description

This randomized, double-blind, controlled trial investigates the effectiveness of amniotic membrane application in reducing post-cesarean complications, including surgical site infections, wound dehiscence, and scar formation. The trial also assesses its impact on pain management and cosmetic outcomes in women aged 18-40 undergoing their first cesarean section. The study was conducted between May 2022 and May 2023 at Van Regional Training and Research Hospital. The amniotic membrane, the innermost layer of the placenta, has regenerative, anti-inflammatory, and antimicrobial properties. Its application during cesarean delivery may offer a cost-effective and autologous intervention to enhance surgical outcomes and patient satisfaction. Objectives: Primary Objectives: 1. Evaluate whether the amniotic membrane reduces surgical complications, including infections, hematoma, and wound dehiscence. 2. Investigate its role in preventing hypertrophic scars and keloids. Secondary Objectives: 1. Assess the effect of amniotic membrane application on postoperative pain levels using the Visual Analog Scale (VAS). 2. Measure patient satisfaction with cosmetic results using the Modified Hollander Wound Evaluation Scale. Methodology: A total of 372 participants were enrolled and randomized into two groups (1:1 ratio) using block randomization to ensure balanced allocation. The intervention group received an amniotic membrane, harvested intraoperatively from the placenta and applied directly to the cesarean incision site before closure. The control group underwent cesarean delivery without membrane application. Both groups were blinded to their assignments, and standard postoperative wound care was provided. Participants were evaluated at multiple predefined postoperative time points (days 1, 2, 7, 40, and 6 months) for surgical site infections, wound dehiscence, scar/keloid formation, pain levels, and cosmetic satisfaction. Significance: This study provides evidence supporting the use of autologous amniotic membranes in obstetrics, potentially establishing a low-cost, accessible method to improve surgical outcomes and patient quality of life. If successful, these findings may have broader implications for other surgical fields and high-risk patient populations.

Conditions

Interventions

TypeNameDescription
OTHERAmniotic Membrane ApplicationAmniotic Membrane Application: This intervention involves the application of an amniotic membrane harvested intraoperatively from the fetal side of the placenta during cesarean delivery. The membrane is placed directly on the incision site before surgical closure to promote wound healing and reduce complications such as infection, dehiscence, and scarring. The membrane is removed 24 hours postoperatively, and standard wound care is continued thereafter.

Timeline

Start date
2022-05-20
Primary completion
2023-05-20
Completion
2023-05-20
First posted
2025-01-13
Last updated
2025-01-13

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06770946. Inclusion in this directory is not an endorsement.